Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2024 07:01 ET | Source: Trevena Inc.

Trevena Reports Third Quarter 2024 Results and Provides Business Update

CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
April 20, 2022 07:00 ET | Source: Trevena Inc.

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data replicate observations previously seen in a...
April 18, 2022 07:00 ET | Source: Trevena Inc.

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
April 13, 2022 16:05 ET | Source: Trevena Inc.

OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
March 31, 2022 07:02 ET | Source: Trevena Inc.

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
March 31, 2022 07:00 ET | Source: Trevena Inc.

Trevena Reports Fourth Quarter and Full Year 2021 Results

-- OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed new Chief Commercial Officer Topline data of OLINVYK vs IV morphine in high-risk...
March 30, 2022 07:00 ET | Source: Trevena Inc.

Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

CHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
February 03, 2022 07:00 ET | Source: Trevena Inc.

Trevena to Present at the 2022 BIO CEO & Investor Conference

CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
January 27, 2022 09:00 ET | Source: Trevena Inc.

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon...
January 03, 2022 16:05 ET | Source: Trevena Inc.

Trevena to Participate in the Upcoming January Conferences

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...

Next Page keyboard_arrow_right